The scoop on Walmart's latest health venture
Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and
Today in healthcare news: Walmart's quietly building a startup that wants to use data to help customers make healthier choices, a senior living chain is requiring employees to get shots, and Verve's building a gene-editing treatment for heart disease.
Walmartis building a new health venture through its incubation arm Store No.8, Business Insider has learned.
- The venture, which doesn't have a name yet, will aim to help shoppers make healthier choices based on their own shopping data.
- It builds on Walmart's healthcare business, which includes clinics and pharmacies.
A major chain of senior living facilities will require more than 10,000 workers to get COVID-19 shots
- Atria Senior Living, a large operator of independent living, assisted living, and other
senior livingfacilities, is requiring more than 10,000 US employees to get the COVID-19 vaccine.
- Atria CEO John Moore told Business Insider that requiring the vaccine is "the responsible thing to do" to stop the spread of the coronavirus among staff and residents.
- Several other long-term care companies told Business Insider they are not mandating the coronavirus vaccine.
- Employers can require staff to give COVID-19 shots without running afoul of the law, according to federal guidance, and more employers are expected to follow in Atria's footsteps.
Verve is gearing up to test a gene-editing treatment that could cure heart disease. The CEO shares his 3-step vision for the one-and-done heart treatment.
- A buzzy Cambridge, Massachusetts biotech is advancing its research on a gene-editing treatment for heart disease.
Verve TherapeuticsCEO Sekar Kathiresan outlined the company's three-stage strategy to ultimately cure heart disease.
- Verve's first treatment candidate uses a next-generation gene-editing tool called base-editing to change a single letter in a person's genetic code. That edit will lower levels of bad cholesterol, the company hopes.
More stories we're reading:
- One of digital health's only dedicated early-stage venture firms just raised $200 million for its second fund. Here's how founder Lynne Chou O'Keefe plans to spend it. (Business Insider)
- Uber and Lyft are pushing for a role in vaccine rollout (The Wall Street Journal)
- Answers to your 24 most burning questions about the coronavirus vaccine, from side effects and costs to when you'll be able to get one (Business Insider)
- One of Intarcia's key investors wrote down its stake former unicorn Intarcia (Stat News)
- DBS Bank’s custom financing leads the way for companies trying to reach net-zero goals
- Republic Day 2022 – Here is a list of wishes and messages you can send to your fellow citizens
- The world's 5 richest tech tycoons — including Elon Musk, Jeff Bezos, and Bill Gates — have already lost about $85 billion this year amid a brutal market sell-off
- OPINION: Experts’ guide to understanding the role of DeFi in digital finance
- OpenSea is returning the millions users lost due to a bug
- Indian crypto exchanges, influencers fall prey to hacks promoting crypto scam
- OPINION: Tax consolidation schemes is the need of the hour for India’s renewable energy sector
- Brands celebrate Republic Day with patriotic fervour